Ascendis Pharma AS (ASND)vsNovartis AG ADR (NVS)
ASND
Ascendis Pharma AS
$210.45
-3.83%
HEALTHCARE · Cap: $13.32B
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6435% more annual revenue ($56.58B vs $865.78M). ASND leads profitability with a 57.3% profit margin vs 23.9%. NVS trades at a lower P/E of 20.6x. ASND earns a higher WallStSmart Score of 55/100 (C).
ASND
Buy55
out of 100
Grade: C
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ASND.
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 104 in profit
Keeps 57 of every $100 in revenue as profit
Revenue surging 144.3% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Elevated debt levels
Weak financial health signals
Trading at 23.3x book value
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ASND
The strongest argument for ASND centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 57.3% and operating margin at 10.1%. Revenue growth of 144.3% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : ASND
The primary concerns for ASND are EPS Growth, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.84 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
ASND profiles as a growth stock while NVS is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
ASND is growing revenue faster at 144.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
ASND scores higher overall (55/100 vs 49/100), backed by strong 57.3% margins and 144.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascendis Pharma AS
HEALTHCARE · BIOTECHNOLOGY · USA
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?